These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 3337897

  • 1. Restriction of cell lysis by homologous complement: II. Protection of erythrocytes against lysis by newly activated complement.
    Houle JJ, Hoffmann EM, Esser AF.
    Blood; 1988 Feb; 71(2):287-92. PubMed ID: 3337897
    [Abstract] [Full Text] [Related]

  • 2. Restriction of cell lysis by homologous complement: I. An analysis of membrane attack complex formation on target membranes.
    Houle JJ, Hoffmann EM, Esser AF.
    Blood; 1988 Feb; 71(2):280-6. PubMed ID: 3337896
    [Abstract] [Full Text] [Related]

  • 3. The role of the C9b domain in the binding of C9 molecules to EAC1-8 defined by monoclonal antibodies to C9.
    Yoden A, Moriyama T, Inoue K, Inai S.
    J Immunol; 1988 Apr 01; 140(7):2317-21. PubMed ID: 3351301
    [Abstract] [Full Text] [Related]

  • 4. Species-restricted target cell lysis by human complement: complement-lysed erythrocytes from heterologous and homologous species differ in their ratio of bound to inserted C9.
    Hu VW, Shin ML.
    J Immunol; 1984 Oct 01; 133(4):2133-7. PubMed ID: 6470486
    [Abstract] [Full Text] [Related]

  • 5. Human protectin (CD59), an 18,000-20,000 MW complement lysis restricting factor, inhibits C5b-8 catalysed insertion of C9 into lipid bilayers.
    Meri S, Morgan BP, Davies A, Daniels RH, Olavesen MG, Waldmann H, Lachmann PJ.
    Immunology; 1990 Sep 01; 71(1):1-9. PubMed ID: 1698710
    [Abstract] [Full Text] [Related]

  • 6. The modifications of the final stages of the complement reaction by alkali metal cations.
    Dalmasso AP, Lelchuk R, Giavedoni EB, De Isola ED.
    J Immunol; 1975 Jul 01; 115(1):63-8. PubMed ID: 239058
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of homologous complement by CD59 is mediated by a species-selective recognition conferred through binding to C8 within C5b-8 or C9 within C5b-9.
    Rollins SA, Zhao J, Ninomiya H, Sims PJ.
    J Immunol; 1991 Apr 01; 146(7):2345-51. PubMed ID: 1706395
    [Abstract] [Full Text] [Related]

  • 8. C5b-9 assembly: average binding of one C9 molecule to C5b-8 without poly-C9 formation generates a stable transmembrane pore.
    Bhakdi S, Tranum-Jensen J.
    J Immunol; 1986 Apr 15; 136(8):2999-3005. PubMed ID: 3958488
    [Abstract] [Full Text] [Related]

  • 9. Mechanism of complement-induced cell lysis. Demonstration of a three-step mechanism of EAC1-8 cell lysis by C9 and of a non-osmotic swelling of erythrocytes.
    Valet G, Opferkuch W.
    J Immunol; 1975 Oct 15; 115(4):1028-33. PubMed ID: 809505
    [Abstract] [Full Text] [Related]

  • 10. Homologous restriction factor: effect on complement C8 and C9 uptake and lysis.
    Zalman LS, Müller-Eberhard H.
    Mol Immunol; 1994 Mar 15; 31(4):301-5. PubMed ID: 8139583
    [Abstract] [Full Text] [Related]

  • 11. Membrane factors responsible for homologous species restriction of complement-mediated lysis: evidence for a factor other than DAF operating at the stage of C8 and C9.
    Shin ML, Hänsch G, Hu VW, Nicholson-Weller A.
    J Immunol; 1986 Mar 01; 136(5):1777-82. PubMed ID: 2419414
    [Abstract] [Full Text] [Related]

  • 12. On the mechanism of cell membrane damage by complement: evidence on insertion of polypeptide chains from C8 and C9 into the lipid bilayer of erythrocytes.
    Hammer CH, Shin ML, Abramovitz AS, Mayer MM.
    J Immunol; 1977 Jul 01; 119(1):1-8. PubMed ID: 559700
    [Abstract] [Full Text] [Related]

  • 13. Vitronectin-mediated inhibition of complement: evidence for different binding sites for C5b-7 and C9.
    Milis L, Morris CA, Sheehan MC, Charlesworth JA, Pussell BA.
    Clin Exp Immunol; 1993 Apr 01; 92(1):114-9. PubMed ID: 7682159
    [Abstract] [Full Text] [Related]

  • 14. Analysis of C5b-8 binding sites in the C9 molecule using monoclonal antibodies: participation of two separate epitopes of C9 in C5b-8 binding.
    Hatanaka M, Seya T, Yoden A, Fukamoto K, Semba T, Inai S.
    Mol Immunol; 1992 Apr 01; 29(7-8):911-6. PubMed ID: 1378934
    [Abstract] [Full Text] [Related]

  • 15. On the mechanism of cytolysis by complement: evidence on insertion of C5b and C7 subunits of the C5b,6,7 complex into phospholipid bilayers of erythrocyte membranes.
    Hammer CH, Nicholson A, Mayer MM.
    Proc Natl Acad Sci U S A; 1975 Dec 01; 72(12):5076-80. PubMed ID: 1061092
    [Abstract] [Full Text] [Related]

  • 16. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9.
    Rollins SA, Sims PJ.
    J Immunol; 1990 May 01; 144(9):3478-83. PubMed ID: 1691760
    [Abstract] [Full Text] [Related]

  • 17. Measurement of the ratio of the eighth and ninth components of human complement on complement-lysed membranes.
    Stewart JL, Monahan JB, Brickner A, Sodetz JM.
    Biochemistry; 1984 Aug 28; 23(18):4016-22. PubMed ID: 6487588
    [Abstract] [Full Text] [Related]

  • 18. Complement lysis of U937, a nucleated mammalian cell line in the absence of C9: effect of C9 on C5b-8 mediated cell lysis.
    Morgan BP, Imagawa DK, Dankert JR, Ramm LE.
    J Immunol; 1986 May 01; 136(9):3402-6. PubMed ID: 3514758
    [Abstract] [Full Text] [Related]

  • 19. Membrane fluidity change in erythrocytes induced by complement system.
    Nakamura M, Ohnishi S, Kitamura H, Inai S.
    Biochemistry; 1976 Nov 02; 15(22):4838-43. PubMed ID: 186096
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the lytic action of cell-bound terminal complement components by human high density lipoproteins and apoproteins.
    Rosenfeld SI, Packman CH, Leddy JP.
    J Clin Invest; 1983 Apr 02; 71(4):795-808. PubMed ID: 6403580
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.